Study of Antibiotic Utilization Measures and Control of ESBLs in China

Wyeth is now a wholly owned subsidiary of Pfizer300 enrolled

Overview

A single-center, prospective, comparative, antibiotic intervention study for patients admitted to MICU1 and MICU2

1. To determine the value of using β-lactamases inhibitors in reducing the cases of ESBL producing E. coli or K. pneumoniae colonization and infection after 12 months. 2. To compare the acquisition rates of ESBL producing E. coli or K. pneumoniae at MICU1 and MICU2 after 12 months

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

300

Conditions

ICU Patient

Interventions

Third generation cephalosporinsDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * All patients admitted or transferred to the ICU/burn units. * Patients of either sex, 18 years of age or older. Exclusion Criteria: * Patient with hypersensitivity to penicillins, cephalosporins, and beta-lactamase inhibitors.

Outcomes

Primary Outcomes

For both MICU1 and MICU2 (acquisition), all culture results will be collected and recorded, then analyzed to determine the ESBL acquisition rate and bacterial isolates (E. coli or K. pneumoniae).

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.